Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Liabilities
Everything the company owes to creditors and other parties.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 91.3% from a year ago
Total liabilities stood at $78.01M at the end of Q1 FY2026, up 91.3% from a year earlier and up 85.0% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.
Context
- Total liabilities amounted to 18.6% of total assets at the end of Q1 FY2026, up 6.3 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +91.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 42.16M USD
- Year-over-year change
- -3.4%
- 3-year CAGR
- -4.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.16M | -3.4% |
| FY2024 | 2024-12-31 | 43.64M | -29.0% |
| FY2023 | 2023-12-31 | 61.45M | +26.7% |
| FY2022 | 2022-12-31 | 48.51M | — |
Total Liabilities vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +91.3% is the highest of 8, against a peer median of +20.2%.
- Total liabilities amounts to 18.6% of total assets for MAZE, versus a peer median of 70.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.42B USD | +20.2% | +14.8% | 105.1% | |
| Sep 2026 | $825.65M USD | +77.6% | -8.0% | 97.3% | |
| Mar 2026 | $355.89M USD | +34.5% | +53.9% | 70.5% | |
| Dec 2025 | €277.91M EUR | +23.2% | +57.9% | 111.7% | |
SEPNSepterna, Inc. | Sep 2026 | $191.48M USD | -12.1% | +38.7% | 30.9% |
| Mar 2026 | $78.01M USD | +91.3% | -4.6% | 18.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $18.53M USD | -39.6% | -45.5% | 4.7% |
| Mar 2026 | $5.85M USD | +19.9% | +27.0% | 11.0% | |
| Peer median (excluding MAZE) | — | +20.2% | +27.0% | 70.5% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.